NCT01752855View on ClinicalTrials.gov

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

New formulation adalimumab

New formulation adalimumab 40 mg every other week

Trial Locations (20)

1200

Site Reference ID/Investigator# 92053, Brussels

4000

Site Reference ID/Investigator# 92054, Liège

19152

Site Reference ID/Investigator# 92116, Philadelphia

29406

Site Reference ID/Investigator# 92114, Charleston

40882

Site Reference ID/Investigator# 92073, Ratingen

67203

Site Reference ID/Investigator# 92117, Wichita

85202

Site Reference ID/Investigator# 92113, Mesa

92543

Site Reference ID/Investigator# 92118, Hemet

97405

Site Reference ID/Investigator# 92096, Banská Bystrica

100337

Site Reference ID/Investigator# 92094, Ploieşti

400006

Site Reference ID/Investigator# 92095, Cluj-Napoca

07012

Site Reference ID/Investigator# 92115, Clifton

638 00

Site Reference ID/Investigator# 91954, Brno

128 50

Site Reference ID/Investigator# 91955, Prague

686 01

Site Reference ID/Investigator# 91953, Uherské Hradiště

760 01

Site Reference ID/Investigator# 91956, Zlín

00693

Site Reference ID/Investigator# 92074, Vega Baja

020475

Site Reference ID/Investigator# 92093, Bucharest

905 01

Site Reference ID/Investigator# 92097, Senica

010 01

Site Reference ID/Investigator# 92098, Žilina

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01752855 - Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab | Biotech Hunter | Biotech Hunter